Hershey’s Plans Look Ambitious in Light of Sugar Backlash

June 25, 2012

On Monday, food-giant Hershey established a few long-term growth targets. But are they attainable?

Arena Pharmaceuticals’ Belviq Approval May Not Match The Hype

June 24, 2012

This article was dual-published on Valuentum’s website and Seeking Alpha’s website June 29, 2012 (archive). Arena Pharmaceuticals (ARNA) had its Belviq obesity drug approved on Wednesday. Shares rallied to close up over 28%, and Belviq is the first weight-loss drug approved by the Food & Drug Administration in 13 years. We do not cover the firm, but we think there are a few major risks investors should be aware of before establishing a position in the biotech firm. For one, Belviq is no wonder drug. With diet and exercise, it was proven to aid in weight-loss of 5% or more of body mass in one year. Perhaps the drug, which helps alleviate hunger, does aid in the process, but we

Could Weakness in Europe Spell Opportunity for American Companies?

June 24, 2012

Costco announced that it is considering adding locations in Spain, Germany and Italy thanks to cheap real estate and interesting business prospects. Could this be a trend going forward?

Carnival’s Results and Outlook Are Better Than Expected

June 22, 2012

Cruise-liner Carnival reported strong second-quarter earnings on Friday and gave a positive outlook for the remainder of the year. However, we maintain our view that shares are overvalued.

Darden Raises Dividend In Spite of Competitive Concerns

June 22, 2012

Restaurant group Darden reported weak sales on Friday morning. However, the company did raise its quarterly dividend and plans to open 100-110 new restaurants in fiscal year 2013.

ConAgra Reports Strong Fourth-Quarter Results; Future Looks Promising

June 22, 2012

Food giant ConAgra issued solid fourth-quarter results. The firm reported strong growth in commercial and consumer foods, and management guided to earnings growth in its 2013 fiscal year.

Dividend Growth Favorite Medtronic Raises Dividend 7%

June 22, 2012

Medical device-maker Medtronic (MDT) announced that it will increase its quarterly dividend 7% to $0.26 per share. This translates to a pay out of $1.04 per year, or an annual yield of 2.8% at current levels.

CarMax’s Weak Results May Actually Be Positive for Automakers

June 22, 2012

Used-car giant CarMax reported weak results Thursday morning. Oddly, we think this bodes well for new car sales at the automakers. Consumers are flocking toward new cars with used-car prices so high.

Red Hat’s Second Quarter Outlook Misses the Mark

June 21, 2012

Open-source enterprise software-maker Red Hat (RHT) reported results for its first quarter of fiscal year 2013. The firm’s performance exceeded expectations, with earnings coming in at $0.30 per share compared to the Street consensus of $0.27 per share. Revenue came in at $314.7 million, up 19% compared to the first quarter of 2012, and slightly ahead of the Street’s expectations. However, Red Hat reported an outlook below both its previously-issued guidance and the Street’s expectations. The firm guided to second-quarter earnings of $0.28-$0.29 per share, which is roughly in-line with the Street consensus of $0.29. Second-quarter revenue is expected to come in the range of $320-$322 million, well below the consensus of $330.8 million. For the full-year, Red Hat lowered its

Bed Bath & Beyond Beats Estimates, But Its Outlook Falls Short

June 21, 2012

Domestic merchandiser Bed Bath & Beyond beat estimates soundly, but the shares are down big on weaker-than-expected guidance.

Previous Next

About Our Name

But how, you will ask, does one decide what [stocks are] "attractive"? Most analysts feel they must choose between two approaches customarily thought to be in opposition: "value" and "growth,"...We view that as fuzzy thinking...Growth is always a component of value [and] the very term "value investing" is redundant.

                         -- Warren Buffett, Berkshire Hathaway annual report, 1992

At Valuentum, we take Buffett's thoughts one step further. We think the best opportunities arise from an understanding of a variety of investing disciplines in order to identify the most attractive stocks at any given time. Valuentum therefore analyzes each stock across a wide spectrum of philosophies, from deep value through momentum investing. And a combination of the two approaches found on each side of the spectrum (value/momentum) in a name couldn't be more representative of what our analysts do here; hence, we're called Valuentum.



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Valuentum Exclusive publication, ESG Newsletter, and any reports, data and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, data or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor, and does not offer brokerage or investment banking services. The sources of the data used on this website and reports are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum, its employees, and independent contractors may have long, short or derivative positions in the securities mentioned on this website. The High Yield Dividend Newsletter portfolio, ESG Newsletter portfolio, Best Ideas Newsletter portfolio and Dividend Growth Newsletter portfolio are not real money portfolios. Performance, including that in the Valuentum Exclusive publication and additional options commentary feature, is hypothetical and does not represent actual trading. Actual results may differ from simulated information, results, or performance being presented. For more information about Valuentum and the products and services it offers, please contact us at info@valuentum.com.